PE20081250A1 - FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA - Google Patents
FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADAInfo
- Publication number
- PE20081250A1 PE20081250A1 PE2007001663A PE2007001663A PE20081250A1 PE 20081250 A1 PE20081250 A1 PE 20081250A1 PE 2007001663 A PE2007001663 A PE 2007001663A PE 2007001663 A PE2007001663 A PE 2007001663A PE 20081250 A1 PE20081250 A1 PE 20081250A1
- Authority
- PE
- Peru
- Prior art keywords
- receiver
- fgf
- fusions
- modified soluble
- biological activity
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 201000008275 breast carcinoma Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000003328 fibroblastic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940063683 taxotere Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Abstract
SE REFIERE A UNA PROTEINA DE FUSION Fc CON RECEPTOR PARA EL FACTOR DE CRECIMIENTO FIBROBLASTICO (FGF) SOLUBLE MODIFICADA QUE COMPRENDE UNA FUSION DE A) UN FRAGMENTO O DOMINIO SOLUBLE DEL RECEPTOR PARA FGF QUE TIENE UNA SECUENCIA POLIPEPTIDICA SEQ ID Nº: 4; B) UNA REGION Fc DE UNA INMUNOGLOBULINA QUE TIENE UNA SECUENCIA POLIPEPTIDICA SEQ ID Nº: 6; Y C) UNA SECUENCIA ENLAZADORA DE 3 RESTOS DE AMINOACIDOS TAL COMO SAL (SER-ALA-LEU), DONDE AL MENOS EL 5º SITIO DE N-GLICOSILACION DE LA PORCION DEL RECEPTOR PARA FGF ESTA OCUPADO Y COMO MAXIMO 45% DE LOS N-GLICANOS DEL RECEPTOR NO TIENEN GRUPO SIALILO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA DE LA PROTEINA DE FUSION QUE ADEMAS PUEDE CONTENER TAXOL O TAXOTERE. DICHAS PROTEINAS DE FUSION TIENEN ACTIVIDAD ANTIANGIOGENICA Y CITOTOXICA SIENDO UTILES EN EL TRATAMIENTO DE CARCINOMA DE MAMA, COLON, DE RINON, LEUCEMIA, MELANOMA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06291824 | 2006-11-28 | ||
EP07290042 | 2007-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081250A1 true PE20081250A1 (es) | 2008-10-07 |
Family
ID=39431092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001663A PE20081250A1 (es) | 2006-11-28 | 2007-11-27 | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
Country Status (33)
Country | Link |
---|---|
US (3) | US8119770B2 (es) |
EP (1) | EP2092069B2 (es) |
JP (1) | JP2010510801A (es) |
KR (1) | KR20090102769A (es) |
AR (1) | AR063975A1 (es) |
AT (1) | ATE509106T1 (es) |
AU (1) | AU2007326985C1 (es) |
BR (1) | BRPI0719290A2 (es) |
CA (1) | CA2668932A1 (es) |
CL (1) | CL2007003411A1 (es) |
CO (1) | CO6190564A2 (es) |
CR (1) | CR10777A (es) |
CY (1) | CY1112435T1 (es) |
DK (1) | DK2092069T3 (es) |
EA (1) | EA018700B1 (es) |
EC (1) | ECSP099361A (es) |
GT (1) | GT200900137A (es) |
HR (1) | HRP20110503T1 (es) |
IL (1) | IL198480A0 (es) |
MA (1) | MA31143B1 (es) |
MX (1) | MX2009005692A (es) |
MY (1) | MY145914A (es) |
NI (1) | NI200900097A (es) |
NO (1) | NO20092414L (es) |
PE (1) | PE20081250A1 (es) |
PL (1) | PL2092069T3 (es) |
PT (1) | PT2092069E (es) |
RS (1) | RS51911B (es) |
SI (1) | SI2092069T1 (es) |
SV (1) | SV2009003272A (es) |
TN (1) | TN2009000184A1 (es) |
TW (1) | TW200839012A (es) |
WO (1) | WO2008065543A2 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005019434A2 (en) | 2003-08-26 | 2005-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Serine protease inhibitors for treatment of bacterial infections |
NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
BRPI0916904A2 (pt) | 2008-08-04 | 2016-10-11 | Fiveprime Therapeutics Inc | polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos |
EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4 |
US8614183B2 (en) | 2009-11-13 | 2013-12-24 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
KR101910779B1 (ko) * | 2010-11-15 | 2018-10-22 | 파이브 프라임 테라퓨틱스, 인크. | Fgfr1 세포밖 도메인 조합치료 |
AU2015258172B2 (en) * | 2010-11-15 | 2017-01-12 | Five Prime Therapeutics, Inc. | Fgfr1 extracellular domain combination therapies |
US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
EP2655408B1 (en) | 2010-12-23 | 2016-07-06 | Sanofi | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma |
AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
CN102219859B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
KR20200044138A (ko) | 2011-06-24 | 2020-04-28 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
AU2012318247B2 (en) * | 2011-11-14 | 2015-12-17 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
CA2896951A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
KR20160002681A (ko) | 2013-01-16 | 2016-01-08 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 |
US9925240B2 (en) | 2013-03-06 | 2018-03-27 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
IL275376B2 (en) | 2013-03-11 | 2024-01-01 | Genzyme Corp | Polypeptides with hyperglycosidic bonds |
US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
CA2909689A1 (en) * | 2013-05-23 | 2014-11-27 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
EP4036118A1 (en) | 2013-08-01 | 2022-08-03 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
SG10201808158UA (en) | 2014-03-19 | 2018-10-30 | Genzyme Corp | Site-specific glycoengineering of targeting moieties |
JP2017517552A (ja) | 2014-06-13 | 2017-06-29 | ジェネンテック, インコーポレイテッド | 抗癌剤耐性の治療及び防止方法 |
RU2021107536A (ru) * | 2015-11-23 | 2021-07-02 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
US11919938B2 (en) * | 2017-11-30 | 2024-03-05 | Grifols Diagnostic Solutions Inc. | Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1 |
MA51676A (fr) * | 2018-01-26 | 2021-05-05 | Hoffmann La Roche | Protéines de fusion il-22 fc et procédés d'utilisation |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288856A (en) | 1986-11-20 | 1994-02-22 | Pierre Amiguet | Method of isolating acid-stable, biologically active proteins |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
US5288855A (en) * | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5153310A (en) * | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
CA2063431C (en) * | 1989-07-06 | 2002-10-29 | Lewis T. Williams | Receptors for fibroblast growth factors |
EP0529076B1 (en) * | 1990-04-27 | 1995-12-06 | Takeda Chemical Industries, Ltd. | Proteins with fibroblast growth factor receptor activity |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
ATE243253T1 (de) | 1990-07-06 | 2003-07-15 | Rhone Poulenc Rorer Internat H | Rezeptoren der wachstumsfaktoren aus fibroblasten |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US20020045207A1 (en) * | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000046380A2 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
US6612152B2 (en) * | 1999-05-01 | 2003-09-02 | James E. Keaton | Lifting, servicing, and diagnosing automobiles |
US6656738B1 (en) * | 1999-11-17 | 2003-12-02 | Bae Systems Integrated Defense Solutions Inc. | Internal heater for preconcentrator |
CA2412882A1 (en) * | 2000-06-30 | 2002-01-10 | Maxygen Aps | Peptide extended glycosylated polypeptides |
CA2424602C (en) * | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
BRPI0314814C1 (pt) * | 2002-09-27 | 2021-07-27 | Xencor Inc | anticorpo compreendendo uma variante de fc |
WO2005016966A2 (en) | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
JPWO2005035741A1 (ja) * | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
DE102004022895A1 (de) | 2004-05-10 | 2005-12-08 | Adam Opel Ag | Schallabsorbierendes Verkleidungselement |
EP1919950A1 (en) | 2004-07-15 | 2008-05-14 | Xencor, Inc. | Optimized fc variants |
US20060223147A1 (en) * | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
EP1746161A1 (en) * | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
-
2007
- 2007-11-27 CL CL200703411A patent/CL2007003411A1/es unknown
- 2007-11-27 PE PE2007001663A patent/PE20081250A1/es not_active Application Discontinuation
- 2007-11-27 AR ARP070105241A patent/AR063975A1/es not_active Application Discontinuation
- 2007-11-28 EP EP07866627.8A patent/EP2092069B2/en active Active
- 2007-11-28 PL PL07866627T patent/PL2092069T3/pl unknown
- 2007-11-28 CA CA002668932A patent/CA2668932A1/en not_active Abandoned
- 2007-11-28 AU AU2007326985A patent/AU2007326985C1/en not_active Ceased
- 2007-11-28 JP JP2009538805A patent/JP2010510801A/ja active Pending
- 2007-11-28 KR KR1020097013421A patent/KR20090102769A/ko not_active Application Discontinuation
- 2007-11-28 TW TW096145220A patent/TW200839012A/zh unknown
- 2007-11-28 DK DK07866627.8T patent/DK2092069T3/da active
- 2007-11-28 US US12/515,463 patent/US8119770B2/en not_active Expired - Fee Related
- 2007-11-28 RS RS20110324A patent/RS51911B/en unknown
- 2007-11-28 PT PT07866627T patent/PT2092069E/pt unknown
- 2007-11-28 AT AT07866627T patent/ATE509106T1/de active
- 2007-11-28 WO PCT/IB2007/004354 patent/WO2008065543A2/en active Application Filing
- 2007-11-28 SI SI200730682T patent/SI2092069T1/sl unknown
- 2007-11-28 MY MYPI20092137A patent/MY145914A/en unknown
- 2007-11-28 MX MX2009005692A patent/MX2009005692A/es active IP Right Grant
- 2007-11-28 BR BRPI0719290-8A patent/BRPI0719290A2/pt not_active IP Right Cessation
- 2007-11-28 EA EA200970515A patent/EA018700B1/ru not_active IP Right Cessation
-
2009
- 2009-04-30 IL IL198480A patent/IL198480A0/en unknown
- 2009-05-07 CR CR10777A patent/CR10777A/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000184A patent/TN2009000184A1/fr unknown
- 2009-05-20 GT GT200900137A patent/GT200900137A/es unknown
- 2009-05-25 EC EC2009009361A patent/ECSP099361A/es unknown
- 2009-05-26 SV SV2009003272A patent/SV2009003272A/es unknown
- 2009-05-26 CO CO09053830A patent/CO6190564A2/es not_active Application Discontinuation
- 2009-05-27 NI NI200900097A patent/NI200900097A/es unknown
- 2009-06-24 MA MA32042A patent/MA31143B1/fr unknown
- 2009-06-24 NO NO20092414A patent/NO20092414L/no not_active Application Discontinuation
-
2011
- 2011-07-06 HR HR20110503T patent/HRP20110503T1/hr unknown
- 2011-08-09 CY CY20111100764T patent/CY1112435T1/el unknown
-
2012
- 2012-01-11 US US13/348,297 patent/US8481487B2/en not_active Expired - Fee Related
-
2013
- 2013-06-28 US US13/931,184 patent/US20140030265A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081250A1 (es) | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA | |
PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
AR070032A1 (es) | Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1) | |
CO6220870A2 (es) | Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
CL2008003527A1 (es) | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 | |
PE20080352A1 (es) | COMPOSICIONES QUE COMPRENDEN ANTICUERPOS DE c-Met | |
CY1117695T1 (el) | Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2 | |
ATE527353T1 (de) | Pdgf-bindendes polypeptid aus protein a | |
PE20120514A1 (es) | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica | |
EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
RS54299B1 (en) | COMPOSITIONS AND METHODS OF USING THERAPY ANTIBODIES | |
PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
RU2022108079A (ru) | Антитело против garp | |
NZ717847A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
CO6270370A2 (es) | Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 | |
RS54627B1 (en) | CANCER EXPRESSION ANTIBODIES THAT EXPLAIN CLAUDINE 6 | |
AR075896A1 (es) | Anticuerpos anti-her (factor de crecimiento epidermico) | |
SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
UA117807C2 (uk) | ІМУНОКОН'ЮГАТ, ЩО МІСТИТЬ РЕКОМБІНАНТНЕ АНТИТІЛО ДО РЕЦЕПТОРА ЕПІДЕРМАЛЬНОГО ФАКТОРА РОСТУ ЛЮДИНИ (hEGFR), ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА ЙОГО МІСТИТЬ | |
PE20081546A1 (es) | Antagonistas del dr6 | |
AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
AR063153A1 (es) | Anticuerpo monoclonal para prevenir/tratar el cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |